Skip to content
OpenCapital
Get started

Vera Therapeutics VERA Enterprise value

Enterprise value at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$2.68B+65.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$2.01B+78.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.14B+874%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.86B+85.0%
Immunome logo
ImmunomeIMNM
$1.9B+470%

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Calculated from Vera Therapeutics’s reported figures.

$2.9Bmarket cap+$75.0Mtotal debt−$114.4Mcash and equivalents=$2.83B

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's enterprise value?
Vera Therapeutics (VERA) reported enterprise value of $2.83B in Q1 2026.
How has Vera Therapeutics's enterprise value changed year-over-year?
Vera Therapeutics's enterprise value increased by 85.0% year-over-year, from $1.53B to $2.83B.
What is the long-term trend for Vera Therapeutics's enterprise value?
Over 4 years (2021 to 2025), Vera Therapeutics's enterprise value has grown at a 54.6% compound annual growth rate (CAGR), from $580.81M to $3.32B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.